Drug
C1-inhibitor
C1-inhibitor is a pharmaceutical drug with 3 clinical trials. Historical success rate of 33.3%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
2(67%)
Phase Distribution
Ph phase_2
1
33%
Ph early_phase_1
1
33%
Ph phase_4
1
33%
Phase Distribution
1
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(2)
Detailed Status
Terminated2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
33.3%
Most Advanced
Phase 4
Trials by Phase
Early Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 41 (33.3%)
Trials by Status
terminated267%
completed133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_2
Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)
NCT02251041
terminatedearly_phase_1
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
NCT01694381
terminatedphase_4
C1-inhibitor in Allergic ASThma Patients
NCT03051698
Clinical Trials (3)
Showing 3 of 3 trials
NCT02251041Phase 2
Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)
NCT01694381Early Phase 1
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
NCT03051698Phase 4
C1-inhibitor in Allergic ASThma Patients
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3